GSK and Alector Sign $2.2B Collaboration to Develop Therapies for Neurodegenerative Diseases
Shots:
- Alector to receive $700M as up front and is eligible to receive ~$1.5B as milestones. The companies collaborated to co-develop AL001 and AL101 for frontotemporal dementia- ALS- PD and AD
- Alector will lead the development of the therapies through P-II POC while the companies will share development costs for therapies. The companies will co-commercialize therapies and share profits/losses in the US while GSK will retain exclusive commercialization rights outside the US- for which Alector will be eligible for royalties
- Alector will lead commercial efforts associated with AL001 in orphan indications and GSK will lead the commercialization of AL101 in AD & PD
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com